勘误：缺失导致急性髓系白血病对MEK抑制剂产生耐药性。
Erratum: deletion drives acute myeloid leukemia resistance to MEK inhibitors.
作者信息
Smith Amanda M, Zhang Christine R C, Cristino Alexandre S, Grady John P, Fink J Lynn, Moore Andrew S
机构信息
The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia.
Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America.
出版信息
Oncotarget. 2020 Jan 21;11(3):305. doi: 10.18632/oncotarget.27402.
Abstract
[This corrects the article DOI: 10.18632/oncotarget.27206.].
摘要
[本文更正了文章DOI：10.18632/oncotarget.27206。]
相似文献
1
Erratum: deletion drives acute myeloid leukemia resistance to MEK inhibitors.勘误：缺失导致急性髓系白血病对MEK抑制剂产生耐药性。
Oncotarget. 2020 Jan 21;11(3):305. doi: 10.18632/oncotarget.27402.
2
deletion drives acute myeloid leukemia resistance to MEK inhibitors.缺失导致急性髓系白血病对MEK抑制剂产生耐药性。
Oncotarget. 2019 Oct 8;10(56):5755-5767. doi: 10.18632/oncotarget.27206.
3
Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.更正：发现FLT3抑制剂LDD1937作为急性髓性白血病的抗白血病药物。
Oncotarget. 2018 Apr 13;9(28):20219. doi: 10.18632/oncotarget.25141.
4
Correction: The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia.更正：高三尖杉酯碱与伊布替尼对FLT3-ITD突变型急性髓系白血病的联合作用
Oncotarget. 2019 Nov 12;10(61):6641-6642. doi: 10.18632/oncotarget.27310.
5
Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.更正：伴有t(4;12)(q12;p13)的急性髓系白血病：一种侵袭性疾病，常累及血小板衍生生长因子受体A（PDGFRA）和ETS变异体6（ETV6）
Oncotarget. 2018 Sep 28;9(76):34449. doi: 10.18632/oncotarget.26205.
6
Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.更正：抑制由肌醇需求酶1α（IRE1α）驱动的促生存途径是急性髓系白血病中一种有前景的治疗应用。
Oncotarget. 2017 Sep 8;8(38):64651. doi: 10.18632/oncotarget.20707.
7
Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.更正：NKp30表达是用于中危急性髓系白血病患者分层的预后免疫生物标志物。
Oncotarget. 2019 Sep 10;10(52):5493. doi: 10.18632/oncotarget.27198.
8
Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in mutated acute myeloid leukemia.更正：超深度下一代测序检测可测量残留病对突变型急性髓系白血病的临床影响
Oncotarget. 2019 Jan 15;10(5):617. doi: 10.18632/oncotarget.26610.
9
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.LYN 和 PTEN 基因在慢性髓性白血病中的表达及其在治疗策略中的重要性。
Blood Cells Mol Dis. 2014 Feb-Mar;52(2-3):121-5. doi: 10.1016/j.bcmd.2013.09.002. Epub 2013 Oct 3.
10
Correction: Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.更正：通过去甲基化剂增加TIMP3表达可减少急性髓系白血病中可溶性MICA、MICB和ULBP2的脱落，促进自然杀伤细胞介导的免疫识别。
Oncotarget. 2018 Aug 28;9(67):32881. doi: 10.18632/oncotarget.26079.
Zotero 插件